Surgical Science Q2 2023: Industry/OEM sales in line but softness in Educational Products
Research Note
2023-08-24
08:49
Redeye provides its initial take on Surgical Science’s Q2 2023 report, which featured a ‘mixed bag’. We judge that notable positives from the report include c30% y/y Industry/OEM sales growth and EBITDA/EBIT aligning with our expectations. Notable negatives include net sales coming in c5% below our expectations due to c8% lower Educational Products sales than we estimated.
CB
Christian Binder
Disclosures and disclaimers